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Background: Little is known concerning the hospitalisation of all lung cancer patients in
a geographically defined population.
Method: All incident lung cancer patients in the Haugalandet area in South-west Norway from
1990 through 1996 were followed from diagnosis till either death or end of follow-up 1 December
2003. Initial symptoms, anatomical stage, functional performance status, histology, initial treat-
ment, terminal care, number of admissions as well as days of hospitalisation were recorded.
Results: Of a total of 271 patients (57 women) only 16 were still alive at end of follow-up. Median
survival time was 170 days. Mean age at the first admission was 67.4 years (range 21e89 years).
Median number (inter quartile range) of admissions was 3 (2, 5) and total hospitalisation days 35
(18, 58). Altogether 26% of the days in institutional care were spent in nursing homes. The 31
patients surgically treated had the highest number of hospitalisation days: 75 (56, 96). Young
age, low anatomical stage and good performance status at time of diagnosis were associated with
increased use of hospitalisation days. Cox regression analysis showed that treatment interven-
tions and dyspnoea were significant predictors when adjusting for age, tumour stage and perfor-
mance status.
Conclusion: In a population-based cohort of incident lung cancer patients, days in health care
institutions involved a large part (19%) of all survival time for those who died. However, the abso-
lute number was greater for those with small tumours and high functional performance status
which initiated other interventions than palliative treatment.
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1942 K. Skaug et al.Introduction performed on the same or following day, followed byLung cancer is a disease with very high mortality, showing
only minor improvement in the 5-year survival rate the last
40 years.1 There are little published data about factors
influencing the distribution of days of hospitalisation in
community-based studies of lung cancer patients for the
whole course of the disease. In a study of 99 highly selected
small cell lung cancer (SCLC) patients 7% of the time from
confirmed diagnosis to relapse of the disease was spent in
hospital.2 Days of hospitalisation due to terminal care were
not included. Hospitalisation is an important part of the
total health care resources used in the management of lung
cancer patients.3 Several studies3e7 have indicated that
50e80% of the total costs of health care are due to hospi-
talisation, while only 20e50% of the costs are due to diag-
nostic procedures, medical interventions and palliative
care. However, previous reports have shown great variation
in patient selection, study methods and analyses of cost,
thus imposing difficulties in comparisons between studies.3
Since hospitalisation accounts for a substantial part of
the resources used in lung cancer care, knowledge of the
hospitalisation profile would provide valuable information
to health care planners. Furthermore, health personnel and
patients should be aware of the expected duration of stay
in health care institutions away from home and family due
to various treatments.
We collected information on hospitalisation from diag-
nosis till either death or end of follow-up in all incident
patients with lung cancer in a defined hospital area in
Norway. Our aim was to examine whether the use of hospi-
talisation was associated with gender, age, anatomical
stage, functional performance status, symptoms, co-
morbidities, area of residence and treatment. In addition we
examined how many days the terminally ill patients spent in
health care institutions during their last eight weeks of life.
Methods
This is a retrospective study of all incident cases of lung
cancer in the Haugalandet area, Norway from 1st January
1990 until 31st December 1996. Thus, the study may also be
termed an historical cohort study.
Population
Haugalandet is located in South-west Norway consisting of
the city of Haugesund and the nine surrounding municipali-
ties. The hospital district had 100 724 inhabitants of whom
77 337were above 15 years in 1996. Inclusion criteriawere all
new patients in the Norwegian Cancer Registry and in the
hospital records of Haugesund hospital. We excluded hospi-
talized patients diagnosed with lung cancer resident outside
our hospital area. The study was approved by the Regional
Committee for Medical Research of Western Norway.
Patient management
Medical history and clinical examination were obtained on
the day of admission. Spirometry and chest X-ray werecomputer tomography (CT) scanning and bronchoscopy.
Transcutaneous biopsies of peripheral tumours were guided
by CT. Mediastinoscopy was performed by referral to
university hospitals. Anatomical staging was done on basis of
X-ray, CT, bronchoscopy, biopsies and cytological specimens.
Radiation treatment was given at Haukeland University
Hospital, Bergen. Thoracic surgery was for the first five
years performed at Haukeland University Hospital or at
Stavanger University Hospital depending on the patient’s
residence. In addition lung cancer surgery was performed
at Haugesund Hospital the last two years of the study
(1994e96). Chemotherapy was given mainly to patients
with small cell lung cancer. After diagnostic procedures and
initial treatment the patients were discharged from
hospital, and thereafter ambulant followed as outpatients
twice a year. Patients with relapse of the disease were
given best supportive care. Regular treatment with opioids
was initiated in hospital and followed-up in a primary
health care setting. Second line chemotherapy was only
given in exceptional cases. During the time of the study
Haugalandet had no hospice institutions, so terminal care
was provided both in the local hospital, in local nursing
homes and at home. The 16 nursing homes in the munici-
palities were staffed with nurses and served by a physician
at least once weekly. A palliative care nurse specialist
employed at the hospital made home visits to the patients
requesting this service. Patients with advanced disease and
metastasis were offered direct admission to the local
hospital at their own request.
Case record form (CRF)
A case record form was designed to obtain information from
hospitals, nursing homes and general practitioners. The
form included data on sex, age, initial performance status,8
signs and symptoms at the time of diagnosis and end stage.
Stage according to the International Union Against Cancer
(UICC)9 and treatment were recorded as well as the number
and duration of stay in hospital and nursing homes. The CRF
was tested in a pilot study.
Stay in hospitals and nursing homes
The stays were categorized in three groups: (1) diagnostic
hospitalisation, i.e. days in hospital necessary for acquiring
a definite diagnosis; (2) terminal hospitalisation, i.e.
hospital days within the last eight weeks of life; and (3)
Other hospital days. Admission and departure days were
counted as whole hospital days. The days in nursing homes
were counted separately.
Information about death
The date of death for patients was obtained from the official
population registry and the Norwegian Cancer Registry.
Collection of data
The hospital records were reviewed systematically by three
physicians. Information about demography, anatomical
Hospitalisation days in patients with lung cancer in a general population 1943stage, performance status, histology, symptoms, co-
morbidity, living area and treatment was extracted. The
data collection was finalized 1st December 2003.
Data base and statistical methods
The CRF were scanned into a Microsoft Excel Worksheet,
and transferred into SPSS 11.5 in which the analyses were
performed. The differences between the groups of patients
defined by gender, age groups, anatomical stage, perfor-
mance status and histology were examined by using the
Pearson chi-square test for categorical variables and anal-
yses of variance for continuous variables. The associations
of days in hospital with the above mentioned factors as well
as initial symptoms (dyspnoea, cough, reduced physical
condition) were analyzed with KaplaneMeier curves10 and
log rank tests.11 Adjusted hazard ratios (HR) and 95%
confidence intervals (CI) for each factor were estimated
from a multiple Cox regression model12 in a backward,
stepwise selection process.Table 1 Gender, age, staging, performance status, histology an
by use of hospital services in those who died and those alive by 1
Deatha
A. Diagnostic hospitalisation
and died during the first
hospitalisation
B.
an
ho
N 8 11
Age, mean 71.6 70
(years) SDc 11.2 10
Men, n (%) 7(88) 88
Anatomical stage, n (%)
I 0 (0) 5
II 1 (12) 10
III 4 (50) 42
IV 3 (38) 53
Performance status
0 and 1 1 (13) 35
2 5 (62) 34
3 and 4 2 (25) 41
Histology, n (%)
Small cell carcinoma 2 (25) 20
Adenocarcinoma 1 (13) 25
Squamous cell carcinoma 1 (13) 30
Non-differentiated carcinoma 0 (0) 15
Other lung cancer 0 (0) 2
No tissue diagnosis 4 (50) 18
Initial treatment
Surgery (resection) 0 (0) 0
Chemo- and/or radiotherapy 2 (25) 35
Best supportive care 6 (75) 75
a Values presented as n(%) unless indicated otherwise.
b Pearson chi-square test for categorical and analysis of variance fo
c Standard deviation.Results
Of the 271 incident lung cancer patients 171 (63%) were
referred from the primary care doctors, 76 (28%) from
consultants within the local hospital area, 17 (6%) from
other hospitals and health institutions within our health
region, and 7 (3%) from the National Mass Radiography
Service. Sex, age, anatomical stage, performance status,
histology and initial treatment offered to all 271 incident
cases are given in Table 1. Only 57 (21%) were women. The
mean age (standard deviation: SD) at time of referral was
67.4 (11.2) years, with a range from 21 to 89 years.
Of the 255 patients who died, eight (3%) died during
their diagnostic hospitalisation (group A), while 110
patients (41%) also had at least one additional admission
due to terminal care (group B). A third group (C) consisting
of 137 patients (50%) had at least one hospital admission
separate from their diagnostic and their terminal hospital-
isation. Sixteen patients (6%) were living by end of follow-
up December 1st 2003 (group D).d initial treatment in 271 lung cancer patients of Haugalandet
.12.2003.
Alivea Totala Pb
Diagnostic
d terminal
spitalisations
C. Diagnostic,
terminal and
other hospitalisations
D.
0 137 16 271
.4 66.9 50.7 67.4 <0.01
.6 9.3 13.3 11.2
(80) 105(77) 14(88) 214(79) 0.66
<0.01
(5) 33 (24) 12 (75) 50 (19)
(9) 10 (7) 2 (13) 23 (9)
(38) 49 (36) 1 (6) 96 (35)
(48) 45 (33) 1 (6) 102 (38)
<0.01
(32) 74 (54) 15 (94) 125 (46)
(31) 49 (36) 0 (0) 88 (33)
(37) 14 (10) 1 (6) 58 (21)
<0.01
(18) 37 (27) 2 (13) 61 (23)
(23) 29 (23) 5 (31) 75 (28)
(27) 39 (29) 4 (25) 59 (22)
(14) 18 (13) 1 (6) 34 (12)
(2) 7 (5) 4 (25) 13 (5)
(16) 7 (5) 0 (0) 29 (11)
<0.01
(0) 20 (15) 11 (69) 31 (11)
(32) 99 (72) 5 (31) 141 (52)
(68) 18 (13) 0 (0) 99 (37)
r continuous variables.
Figure 2 Distribution of 271 patients with lung cancer by
number of hospital days.
1944 K. Skaug et al.There was no sex difference among these four groups.
However, the age at diagnosis was lower (p< 0.01) in those
still living. Anatomical stage, performance status, histology
and treatment offered differed considerably among the
four groups, with poorer performance status and more
advanced disease in group B (Table 1). Only 37 of the 118
patients in groups A and B were offered active treatment in
addition to best supportive care.
Hospitalisation
We observed as expected a skewed distribution of hospi-
talisations (Fig. 1) as well as days spent in hospital (Fig. 2).
The median (inter quartile range: IQR) hospital admissions
were3(2, 5) and the median length of each hospital stay
7.8(7,15) days. The median days spent in hospital was 35.
The corresponding value was 18.5 days for those who died
during their first hospital stay (A), 21 days for those with
both diagnostic and terminal stays (B) and 27.5 days for
those still living (D). Group C spent much more time in
hospital, median stay 57 days, than the other groups
(Table 2).
Total days in health care institutions
The total number of days of observation of all lung cancer
patients in the present study was 137 774. The median
survival was 170 days (Table 3). The 3911 days spent in
nursing homes and the 11 314 hospital days give a total of
15 225 which means 12% of all days under observation.
However, the percentage of total days away from home
varied greatly (Table 3). Altogether 26% of days in institu-
tional care were spent in nursing homes. The 255 patients
who died during the study period spent 14 568 days in
hospitals or in nursing homes with a total survival of 78 111
days (Table 3). This means that 19% of the time after theirFigure 1 Distribution of 271 patients with lung cancer by
number of hospital admissions.initial admission for lung cancer was spent in health care
institutions.
Distribution of days spent in hospitals
The very different distributions of hospitalisation days for
patients given supportive care, radio- and/or chemo-
therapy, and surgery are clearly shown in Fig. 3. Fifty days
or less were used by 80% of those patients given only
supportive care, while only 25% of the patients given
surgery spent less than 50 days in hospital.
No differences in median hospital days were observed
for those given surgery at Haukeland University Hospital,
Stavanger University Hospital, or Haugesund Hospital. Ten
patients who were given radiotherapy as well as surgery
spent a median of 88 days in hospital, while the 21 patients
without additional radiotherapy spent 69 days. In SCLC 51
patients who got chemotherapy spent a median of 44 days
in hospital, while 10 patients with no chemotherapy spent
22 days (p< 0.01).
Factors associated with hospitalisation days
Patients surgically treated with resection of the lung had
a median (IQR) of 75 (56, 96) days in hospital, those with
chemo and/or radiotherapy had 44 (25, 69) days, while
patients who got only best supportive therapy had only 22
(12, 33) hospitalisation days (Table 4). Younger age, low
stage, good performance status, histology and good
physical condition (judged by a physician) were associated
with more hospitalisation days (Table 4). There was no
difference whether the patients came from urban or rural
areas (data not given). Multivariate survival analyses (Cox
regression) showed that initial dyspnoea and treatment
choices were predictors for increased use of hospital-
isation days (Table 5). Initial patient characteristics were
not associated with hospitalisation in separate analyses of
the diagnostic and the terminal phase of the disease (data
not given).
Table 2 Hospital days per 1.12.2003 in 271 incident lung cancer patients 1990e96 in Haugalandet hospital district by hospital
services and survival.
First diagnostic
hospital stay
Terminal days
excluding hospital
days for diagnosis
Other hospital days
(treatment and
other diseases)
Total hospital
days
A. Death during the first
hospital stay
NZ 8 NZ 8
Total 176 176
Median 18.5 e e 18.5
Range 5e44 5e44
B. Death after hospital admission
for diagnosis and terminal
care the last 56 days
NZ 110 NZ 71 NZ 110
Total 1778 953 2731
Median 12 10 e 21
Range 1e128 1e49 2e128
C. Death after hospital
admission for diagnosis,
terminal care and other
health services
NZ 137 NZ 101 NZ 137 NZ 135
Total 1811 1807 4132 7750
Median 10 14 24 52
Range 1e77 1e56 1e153 8e175
D. Alive NZ 16 NZ 14 NZ 16
Total 157 500 657
Median 7.5 e 30 27.5
Range 2e24 3e115 7e134
Total NZ 271 NZ 172 NZ 151 NZ 271
Total 3922 2760 4632 11314
Median 11 12 24 35
Range 1e128 1e156 1e153 2e175
Table 3 Total days in treatment and care outside homes in 271 lung cancer patients from first hospital admission to death or
end of observation.
Days in nursing
homes
Total days in
hospitals and
nursing homes
Days from first admission
to death or end of
observation (days at risk)
Percentages of total
days in hospital
and nursing homes
A. Death during the first
hospital stay
NZ 8 NZ 8
Total 176 176 100%
Median e 18 18
Range 5e44 5e44
B. Death after hospital
admission for diagnosis
and only terminal care
NZ 30 NZ 110 NZ 110
Total 1316 4047 11 671 35%
Median 21 25 57
Range 1e430 2e456 1e821
C. Death after hospital
admission for diagnosis,
other health services and
terminal care
NZ 39 NZ 137 NZ 137
Total 2595 10 345 66 264 17%
Median 46 61 260
Range 5e252 9e285 27e3311
D. Alive NZ 16 NZ 16
Total 657 59 663 1%
Median e 27.5 3510
Range 7e134 2925e4766
Total NZ 68 NZ 271 NZ 271
Total 3911 15 225 137 774
Median 32 42 170 12%
Range 1e430 2e456 1e4766
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Figure 3 Fraction of lung cancer population by hospital days
in those with surgery, radio- and/or chemotherapy, and best
supportive care after adjustment for male sex, age from 65 to
74 years, stage III, performance status 2 and non-small cell
carcinoma.
Table 4 Hospital days after onset of lung cancer in 271
patients at Haugalandet.
Number
of patients
Quartiles Log rank
test
p-value
25% 50% 75%
Gender 0.93
Females 57 24 41 60
Males 214 18 36 60
Age (years) <0.01
<65 92 24 43 67
65e75 101 19 40 60
>75 78 16 27 45
Initial stage <0.01
I and II 73 31 60 82
III 96 15 33 57
IV 102 19 8 43
Initial performance
status (WHO)
<0.01
0 and 1 125 25 46 75
2 88 19 33 56
3 and 4 58 9 25 41
Histology <0.01
NSCLSa 181 21 39 64
SCLCb 61 22 40 56
Histology
not verified
29 8 18 29
Initial cough 0.86
Present 112 18 39 60
Not present 159 19 36 60
Initial dyspnoea 0.89
Present 117 17 38 60
Not present 154 19 36 60
Deterioration in
physical condition
<0.01
Present 144 17 28 49
Not present 127 24 45 72
Treatment <0.01
Surgery (resection) 31 56 75 96
Chemo- and/or
radiotherapy
141 25 44 69
Best supportive
care only
99 12 22 33
a Non-small cell lung cancer.
b Small cell lung cancer.
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In the present study we have followed a population-based
cohort of 271 lung cancer patients for a minimum of 7 up to
a maximum of 14 years. Sixteen patients who survived
spent a median of 27.5 days in hospital. The 255 patients
who died spent 19% of their remaining life time in health
institutions and as much as 42% of all days in the terminal 8
weeks. A great variability was observed in the number and
length of the hospital stays.
The strengths are that our study was population based
and contained complete information about days in hospitals
as well as in nursing homes, thus establishing an historical
cohort. Furthermore, the long follow-up gives our study
additional weight. The three unambiguous categories of
hospital stays are a simplification of a previous SCLC study13
with six phases from referral to terminal care (Tables 1e3).
Our management model for the individual patient was an
integrated model for life-prolonging and palliative care.14
The limitations of our study were its retrospective
nature and the rather limited number of patients being
offered surgical resection. Only 11% of our patients were
operated on while in all histology-verified lung cancer cases
in Norway in 1993e2002 as many as 16% were surgically
treated.15 This might have given us slightly fewer hospi-
talisation days. A truly prospective study could have
improved the quality of data on the characteristics of the
patients, but as patient records in hospitalisations are
obligatory by law in Norway, such a study would still reveal
the same number of admissions and days in hospital.
In 165 lung cancer patients in Germany, Schneider
studied the number and duration of stays retrospectively
the last 5 years before death. A median of 26 hospital days
were found16 which is lower than in our study. The patientselection differed, however, from our study since these
analyses were based on data from only one health insur-
ance company.
In the terminal stage, almost all patients in the present
study had symptoms,17 and almost half of their terminal
eight weeks were spent in hospital or nursing homes. This
differs from a study of lung cancer patients in France18
where terminal care was given in hospitals. Great use of
resources in the terminal stage was also reported by
Oliver13 where hospitalisation accounted for 77% of the
Table 5 Hazard ratio (HR) of fewer hospital days analyzed by Cox regression of 271 lung cancer patients.
Unadjusted Fully adjusted
HRa 95% CIb P HR 95% CI P
Gender 0.990 0.260
Males 1 1
Females 1.00 (0.74,1.35) 1.20 (0.87,1.65)
Age (years) 0.008 0.369
<65 1 1
65e75 1.23 (0.91,1.67) 1.04 (0.75,1.45)
>75 1.67 (1.21,2.30) 1.27 (0.88,1.82)
Initial stage <0.001 0.090
I and II 1 1
III 1.79 (1.29,2.48) 1.44 (0.99,2.09)
IV 2.11 (1.52,2.92) 1.47 (1.00,2.16)
Initial performance status
(WHO)
<0.001 0.081
0 and 1 1 1
2 1.49 (1.12,1.98) 1.09 (0.79,1.49)
3 and 4 2.44 (1.75,3.40) 1.54 (1.05,2.26)
Histology 0.004 0.479
NSCLC c 1 1
SCLC d 1.09 (0.81,1.46) 1.06 (0.76,1.48)
Histology not verified 2.08 (1.40,3.10) 1.31 (0.85.2.03)
Initial cough 0.843 0.097
Present 1 1
Not present 0.98 (0.76,1.25) 0.79 (0.60,1.04)
Initial dyspnoea 0.967 0.014
Present 1 1
Not present 1.00 (0.78,1.28) 1.42 (1.08,1.89)
Deterioration in physical
condition
0.002 0.443
Present 1 1
Not present 0.67 (0.52,0.86) 1.13 (0.83,1,55)
Treatment <0.001 <0.001
Surgery (resection) 1 1
Chemo- and/or radiotherapy 2.20 (1.37, 3.53) 1.78 (1.02, 3.12)
Best supportive
care only
6.83 (4.11,11.35) 5.25 (2.73,10.08)
a Hazard ratio.
b Confidence interval.
c Non-small cell lung cancer.
d Small cell lung cancer.
Hospitalisation days in patients with lung cancer in a general population 1947costs in this period. Finally, Guest et al. reported that 63%
of all costs were due to palliative care confirming previous
studies.7,19,20
New treatment options along with our study addressing
the management of lung cancer have initiated changes in
our local hospital. For example, all patients receiving
chemotherapy21,22 are now treated as outpatients in the
chest clinic. However, three cycles of chemotherapy in
advanced non-small cell lung carcinoma (NSCLC) may cause
hospitalisation due to adverse effects in up to half of the
patients.23 Furthermore, radiation treatment is now mainly
given on an outpatient basis.Surgical treatment is discussed in video conferences
with the staff at the regional university hospital including
chest physicians, oncologists, radiologists, pathologists and
thoracic surgeons. The patients are transferred directly
after the initial local diagnostic examination to the
Department of Thoracic Surgery.
Young patients with good performance status, limited
disease and no initial dyspnoea were offered aggressive
treatment and received as expected largest number of days
in hospital. In another study young age was also associated
with higher monthly costs.24 In a population-based study
of lung cancer from Northern Ireland the length of
1948 K. Skaug et al.hospitalisation was shorter in advanced disease25 than in
limited disease confirming our study. Contrary to our study
Dedes et al. (2004) found that patients with advanced
staged disease required the highest cost.20 However, this
study was solely based on chart review of patients referred
to a tertiary care hospital, and was limited to only 30
months follow-up.
We observed that presence of dyspnoea was an inde-
pendent factor for days in hospital. This was to be expected
as dyspnoea needs interventions in hospital with pleural
drainage, supplemental oxygen inhalation or bronchoscopy
evaluating the central airways possibly resulting in a stent
implantation or other local treatment options.
Hospital days are costly and should with optimal inter-
ventions be brought to a minimum also for health
management organizations in a social democracy where
hospitalisations are without personal costs for all patients.
It is simple to measure and population-based studies of lung
cancer with more aggressive treatment in the future should
give estimates of hospitalisation together with days of
survival.
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